Vitalhub (TSE:VHI - Get Free Report) has been assigned a C$13.50 target price by equities researchers at Raymond James in a research note issued to investors on Thursday,BayStreet.CA reports. The brokerage currently has an "outperform" rating on the stock. Raymond James' price target indicates a potential upside of 33.00% from the stock's previous close.
Several other equities research analysts have also recently weighed in on the company. Canaccord Genuity Group upped their target price on Vitalhub from C$12.00 to C$12.50 and gave the stock a "buy" rating in a research note on Thursday, January 16th. Scotiabank set a C$14.00 price target on shares of Vitalhub and gave the company an "outperform" rating in a report on Thursday, January 30th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of C$12.08.
View Our Latest Stock Report on VHI
Vitalhub Price Performance
VHI traded down C$0.09 on Thursday, hitting C$10.15. 154,101 shares of the stock were exchanged, compared to its average volume of 146,944. Vitalhub has a 12 month low of C$5.80 and a 12 month high of C$12.09. The firm has a market capitalization of C$549.04 million, a price-to-earnings ratio of 165.09, a PEG ratio of 1.18 and a beta of 1.26. The business has a 50-day moving average of C$10.48 and a two-hundred day moving average of C$10.35.
Vitalhub Company Profile
(
Get Free Report)
Vitalhub Corp., together with its subsidiaries, provides technology solutions for health and human service providers in Canada, the United States, the United Kingdom, Australia, Western Asia, and internationally. Its solutions include electronic healthcare record, case management, care coordination and optimization, and patient flow, engagement, and operational visibility solutions.
Further Reading
Before you consider Vitalhub, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vitalhub wasn't on the list.
While Vitalhub currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
